Komori
Share Issuance and Disposal4564OncoTherapy Science,Inc.Pharmaceuticals

Monthly Exercise Status of the 38th Stock Acquisition Rights with Exercise Price Adjustment Clause Issued through a Third-Party Allotment

In June 2026, 96,000 of the 38th Stock Acquisition Rights were exercised, and 9.6 million new shares were issued. The unexercised balance at month-end was 150,000 rights, equivalent to 15 million shares.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
9600000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)

発行・処分する株式数9,600,000Shares

Shares issued during the month: 9,600,000 shares (new shares); treasury shares transferred: —

Existing Shares and Increase
+2.83%Rate of increase
398,643,700 shares408,243,700Shares

Exercise ratio subject to exercise restrictions: 2.83% (①9,600,000 shares / ②338,643,700 shares)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Subject to an Exercise Price Adjustment Clause. The exercise price during the target month was ¥17.7 or ¥19.6. The adjustment floor is Not disclosed
Number of Stock Acquisition Rights
Total issued: 795,000 rights (calculated from 96,000 rights, equivalent to 12.06% of the total issued); unexercised at the end of the preceding month: 246,000 rights; unexercised at the end of the target month: 150,000 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
Timing 8 December 2025 / Type Stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalStock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
Number of shares to be issued or disposed ofShares issued during the month: 9,600,000 shares (new shares); treasury shares transferred: —
Dilution RateExercise ratio subject to exercise restrictions: 2.83% (①9,600,000 shares / ②338,643,700 shares)
Total number of issued shares398,643,700 shares (as of the end of the month preceding the target month) → 408,243,700 shares (calculated as of the end of the target month)(Approximately 2.41%)
Exercise priceSubject to an Exercise Price Adjustment Clause. The exercise price during the target month was ¥17.7 or ¥19.6. The adjustment floor is Not disclosed
Number of Stock Acquisition RightsTotal issued: 795,000 rights (calculated from 96,000 rights, equivalent to 12.06% of the total issued); unexercised at the end of the preceding month: 246,000 rights; unexercised at the end of the target month: 150,000 rights
Procedures under the Corporate Code of ConductThe disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financingTiming 8 December 2025 / Type Stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

This is a report on the monthly exercise status, and the company has provided no explanation of the reasons for the exercises.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Monthly Exercise Status of the 38th Stock Acquisition Rights with Exercise Price Adjustment Clause Issued through a Third-Party Allotment | OncoTherapy Science,Inc. (4564) timely disclosure | Komori